Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
8
SEER Quote, Financials, Valuation and Earnings
Last price:
$1.85
Seasonality move
:
-20.82%
Day range:
$1.72 - $1.83
52-week range:
$1.62 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.24x
P/B ratio:
0.39x
Volume:
292.4K
Avg. volume:
328.1K
1-year change:
-12.62%
Market cap:
$101.3M
Revenue:
$16.6M
EPS (TTM):
-$1.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$4.6M | -$0.32 | -19.14% | -16.62% | $3.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.70 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
CERS
Cerus Corp.
|
$59.3M | -$0.01 | 28.13% | -2.91% | $4.67 |
|
NEPH
Nephros, Inc.
|
$4.5M | $0.01 | 15.01% | -69.79% | $6.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$1.80 | $3.00 | $101.3M | -- | $0.00 | 0% | 6.24x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.50 | $31.70 | $3.8B | 9.83x | $0.00 | 0% | 3.56x |
|
AGEN
Agenus, Inc.
|
$3.18 | $12.33 | $114.9M | -- | $0.00 | 0% | 0.80x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.65 | $457.00 | $42.3B | 141.18x | $0.00 | 0% | 11.45x |
|
CERS
Cerus Corp.
|
$2.13 | $4.67 | $409.1M | -- | $0.00 | 0% | 1.97x |
|
NEPH
Nephros, Inc.
|
$3.87 | $6.50 | $41.1M | 28.02x | $0.00 | 0% | 2.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
8.36% | 1.603 | 22.98% | 12.12x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
CERS
Cerus Corp.
|
60.15% | 1.073 | 24.45% | 0.82x |
|
NEPH
Nephros, Inc.
|
10.34% | 3.227 | 2.3% | 3.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SEER
Seer, Inc. (California)
|
$2.2M | -$17.4M | -23.26% | -25.24% | -413.83% | -$7.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
CERS
Cerus Corp.
|
$29.7M | -$7.5M | -9.92% | -26.37% | -3.58% | $94K |
|
NEPH
Nephros, Inc.
|
$2.9M | $314K | 14.16% | 16.22% | 6.59% | $99K |
Seer, Inc. (California) vs. Competitors
-
Which has Higher Returns SEER or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -380.72% compared to Seer, Inc. (California)'s net margin of 96.33%. Seer, Inc. (California)'s return on equity of -25.24% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.96% -$0.29 $283M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SEER or ACAD?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 66.67%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.70 which suggests that it could grow by 40.89%. Given that Seer, Inc. (California) has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Seer, Inc. (California) is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is SEER or ACAD More Risky?
Seer, Inc. (California) has a beta of 1.660, which suggesting that the stock is 66.047% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock SEER or ACAD?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or ACAD?
Seer, Inc. (California) quarterly revenues are $4.2M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Seer, Inc. (California)'s net income of -$16M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.24x versus 3.56x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.24x -- $4.2M -$16M ACADACADIA Pharmaceuticals, Inc.3.56x 9.83x $284M $273.6M
-
Which has Higher Returns SEER or AGEN?
Agenus, Inc. has a net margin of -380.72% compared to Seer, Inc. (California)'s net margin of -116.82%. Seer, Inc. (California)'s return on equity of -25.24% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.96% -$0.29 $283M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About SEER or AGEN?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 66.67%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 287.84%. Given that Agenus, Inc. has higher upside potential than Seer, Inc. (California), analysts believe Agenus, Inc. is more attractive than Seer, Inc. (California).
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 AGENAgenus, Inc.2 1 0 -
Is SEER or AGEN More Risky?
Seer, Inc. (California) has a beta of 1.660, which suggesting that the stock is 66.047% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock SEER or AGEN?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or AGEN?
Seer, Inc. (California) quarterly revenues are $4.2M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Seer, Inc. (California)'s net income of -$16M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.24x versus 0.80x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.24x -- $4.2M -$16M AGENAgenus, Inc.0.80x -- $30.2M $63.9M
-
Which has Higher Returns SEER or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -380.72% compared to Seer, Inc. (California)'s net margin of 16.99%. Seer, Inc. (California)'s return on equity of -25.24% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.96% -$0.29 $283M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SEER or ALNY?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 66.67%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 43.42%. Given that Seer, Inc. (California) has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Seer, Inc. (California) is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is SEER or ALNY More Risky?
Seer, Inc. (California) has a beta of 1.660, which suggesting that the stock is 66.047% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock SEER or ALNY?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or ALNY?
Seer, Inc. (California) quarterly revenues are $4.2M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Seer, Inc. (California)'s net income of -$16M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.24x versus 11.45x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.24x -- $4.2M -$16M ALNYAlnylam Pharmaceuticals, Inc.11.45x 141.18x $1.1B $186.4M
-
Which has Higher Returns SEER or CERS?
Cerus Corp. has a net margin of -380.72% compared to Seer, Inc. (California)'s net margin of -3.78%. Seer, Inc. (California)'s return on equity of -25.24% beat Cerus Corp.'s return on equity of -26.37%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.96% -$0.29 $283M CERSCerus Corp.51.51% -- $161.9M -
What do Analysts Say About SEER or CERS?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 66.67%. On the other hand Cerus Corp. has an analysts' consensus of $4.67 which suggests that it could grow by 119.09%. Given that Cerus Corp. has higher upside potential than Seer, Inc. (California), analysts believe Cerus Corp. is more attractive than Seer, Inc. (California).
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 CERSCerus Corp.3 1 0 -
Is SEER or CERS More Risky?
Seer, Inc. (California) has a beta of 1.660, which suggesting that the stock is 66.047% more volatile than S&P 500. In comparison Cerus Corp. has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.144%.
-
Which is a Better Dividend Stock SEER or CERS?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cerus Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Cerus Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or CERS?
Seer, Inc. (California) quarterly revenues are $4.2M, which are smaller than Cerus Corp. quarterly revenues of $57.8M. Seer, Inc. (California)'s net income of -$16M is lower than Cerus Corp.'s net income of -$2.2M. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Cerus Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.24x versus 1.97x for Cerus Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.24x -- $4.2M -$16M CERSCerus Corp.1.97x -- $57.8M -$2.2M
-
Which has Higher Returns SEER or NEPH?
Nephros, Inc. has a net margin of -380.72% compared to Seer, Inc. (California)'s net margin of 7.07%. Seer, Inc. (California)'s return on equity of -25.24% beat Nephros, Inc.'s return on equity of 16.22%.
Company Gross Margin Earnings Per Share Invested Capital SEERSeer, Inc. (California)51.96% -$0.29 $283M NEPHNephros, Inc.60.47% $0.03 $11.2M -
What do Analysts Say About SEER or NEPH?
Seer, Inc. (California) has a consensus price target of $3.00, signalling upside risk potential of 66.67%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 67.96%. Given that Nephros, Inc. has higher upside potential than Seer, Inc. (California), analysts believe Nephros, Inc. is more attractive than Seer, Inc. (California).
Company Buy Ratings Hold Ratings Sell Ratings SEERSeer, Inc. (California)1 0 0 NEPHNephros, Inc.1 0 0 -
Is SEER or NEPH More Risky?
Seer, Inc. (California) has a beta of 1.660, which suggesting that the stock is 66.047% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.420, suggesting its more volatile than the S&P 500 by 41.997%.
-
Which is a Better Dividend Stock SEER or NEPH?
Seer, Inc. (California) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seer, Inc. (California) pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SEER or NEPH?
Seer, Inc. (California) quarterly revenues are $4.2M, which are smaller than Nephros, Inc. quarterly revenues of $4.8M. Seer, Inc. (California)'s net income of -$16M is lower than Nephros, Inc.'s net income of $337K. Notably, Seer, Inc. (California)'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 28.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seer, Inc. (California) is 6.24x versus 2.32x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SEERSeer, Inc. (California)6.24x -- $4.2M -$16M NEPHNephros, Inc.2.32x 28.02x $4.8M $337K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
